Enliven shareholders approve 2.9M share increase in equity plan and officer exculpation amendment

Enliven Therapeutics, Inc.

Stockholders approved amendment to 2020 Equity Incentive Plan, increasing authorized shares by 2,900,000.
Certificate of Incorporation amended to limit officer liability for monetary damages under Delaware law.
Class I directors Mika Derynck (36.4M for) and Rishi Gupta (37.4M for) elected to 2027 annual meeting.
Deloitte & Touche LLP ratified as independent auditor for FY 2024 with 42.9M votes for.
All proposals passed; broker non-votes 4.6M on director elections and other items.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.